Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 3Recurrence 1Meningeal Neoplasms 1Inhibition, Psychological 1Hereditary Sensory and Autonomic Neuropathies 1Glioma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Everolimus 2lorlatinib 1liposomal doxorubicin 1encorafenib 1binimetinib 1Taxes 1Radiotherapy 1Paclitaxel 1Lomustine 1Irinotecan 1Gemcitabine 1Doxorubicin 1Cetuximab 1Carboplatin 1Albumin-Bound Paclitaxel 1AZD1390 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × AZD1390 × CNS × Clear all
NCT03423628 2025-12-22

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

AstraZeneca

Phase 1 Recruiting
180 enrolled
CNS

Brain Neoplasms, Glioblastoma, Inhibition, Psychological, Meningeal Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡